Home › Compare › SKLKF vs ABBV
SKLKF yields 0.90% · ABBV yields 3.09%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, SKLKF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SKLKF + ABBV for your $10,000?
Shinsei Bank, Limited provides various banking and financial products and services to individual customers, corporations, public-sector entities, and financial institutions in Japan. It offers Yen/foreign currency deposits, and structured deposits; home mortgages; corporate loans, finance for start-up, real estate non-recourse finance, project finance, renewable energy finance, acquisition finance, ship finance, healthcare finance, sustainable finance/impact finance, M&A related finance, and specialty finance; and loan syndication. The company also provides foreign exchange and derivatives, M&A advisory, credit trading, private equity, business succession and change/closure support services, and wealth management, as well as prepaid and credit cards. In addition, it engages in the provision of trust services, leasing related financial products and services, equity related and other capital markets transactions, securities, asset and wealth management, unsecured loans, housing loans, investment trusts, brokerage, life and non-life insurance, consumer finance products and services, credit guarantee services, installment sales finance, credit cards, loan and payment services, and treasury services. The company was formerly known as The Long-Term Credit Bank of Japan, Limited and changed its name to Shinsei Bank, Limited in June 2000. Shinsei Bank, Limited was incorporated in 1952 and is headquartered in Tokyo, Japan.
Full SKLKF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.